Lux Capital is a stage-agnostic venture firm focused on frontier science and deep technology, investing globally from first experiments through growth rounds. The firm is known for high-conviction bets on technically difficult, non-consensus companies in areas like defense, AI, biotech, aerospace, and industrial systems—backing founders who can turn "sci-fi into sci-fact."
Lux invests when a startup demonstrates a deep technical moat and is led by founders with rare domain expertise—often PhDs or seasoned engineers—pursuing hard problems where compute, automation, or biology create asymmetry. The firm favors non‑consensus theses and technologies that could become critical infrastructure, such as national‑security AI platforms or novel therapeutics. In evaluating deals, Lux places the team and technology above early market traction; at seed stage it will back pre‑product, pre‑revenue companies based on scientific merit, while later stages require clear productization, strategic contracts, or milestone achievements. Deal‑breakers include incremental offerings lacking a hard technical edge, overly crowded markets, and weak founder‑market fit in highly technical domains.
See the rest of how Lux Capital decides.
Evaluation framework, investment themes, pitch guidance and the partner map. One email, no password — we send a link and you land right back here.